RAFAEL HOLDINGS, INC. Share-based Payment Arrangement, Accelerated Cost
RAFAEL HOLDINGS, INC. (RFL) reported Share-based Payment Arrangement, Accelerated Cost of $250.70 thousand for the 9-month period ending 2026-04-30, per its 10-Q filed 2026-06-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost · last filed 2026-06-11
- RAFAEL HOLDINGS, INC. share-based payment arrangement, accelerated cost for the quarter ending 2026-04-30 was $0.00.
- RAFAEL HOLDINGS, INC. share-based payment arrangement, accelerated cost for the quarter ending 2026-01-31 was $0.00.
- RAFAEL HOLDINGS, INC. share-based payment arrangement, accelerated cost for the quarter ending 2025-10-31 was $250.70K.
| Period end | Share-based Payment Arrangement, Accelerated Cost 3 month | Share-based Payment Arrangement, Accelerated Cost 6 month | Share-based Payment Arrangement, Accelerated Cost 9 month |
|---|---|---|---|
| 2026-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-11 | $0.00 derived: sum of 2 quarters · filed 2026-06-11 | $250.70K 10-Q · filed 2026-06-11 |
| 2026-01-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-16 | $250.70K 10-Q · filed 2026-03-16 | |
| 2025-10-31 | $250.70K 10-Q · filed 2025-12-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |